慢性肾脏病5期患者应用不同剂量肾康注射液的临床对比研究

发布时间：2018-11-21 09:37

【摘要】：目的:观察慢性肾脏病5期患者应用不同剂量肾康注射液的临床效果,进而为指导临床实践提供可能的方法和借鉴。方法:选取慢性肾脏病5期患者131例,按随机数字表法分为肾康注射液30ml组30例、肾康注射液60ml组31例、肾康注射液100ml组35例和对照组35例,4组均给予一致的常规对症支持治疗,并采用高通量血液透析进行干预,且在此基础上,观察不同剂量肾康注射液静脉滴注的临床效果。随后比较4组患者的临床疗效、证候评分、尿液电导率、C反应蛋白、肿瘤坏死因子-α、白细胞介素6、不良反应以及3个月后的残余肾功能和生存质量情况。结果:肾康注射液100ml组患者临床疗效、证候评分、尿液电导率、C反应蛋白、肿瘤坏死因子-α、白细胞介素6、残余肾功能及生存质量均较肾康注射液30ml组、肾康注射液60 ml组和对照组显著;同时,4组患者尿液电导率均与尿素氮、肌酐呈负相关并且与血红蛋白量正相关。另外,治疗期间4组均未出现死亡病例,也未发生与肾康注射液相关的药物不良反应。结论:慢性肾脏病5期患者电导率下降、存在微炎症,且与肾功能衰竭的程度正相关。采用肾康注射液1.5ml/kg·d稀释静脉滴注干预高通量血液透析可明显改善慢性肾脏病5期患者临床疗效、证候评分、电导率及微炎症状态,且不良反应少,具有较好保护残余肾功能和提高生存质量的重要意义,建议临床透析治疗应用。
[Abstract]:Objective: to observe the clinical effect of different doses of Shenkang injection in patients with stage 5 chronic kidney disease, and to provide possible methods and references for guiding clinical practice. Methods: one hundred and thirty-one patients with 5 stages of chronic kidney disease were randomly divided into Shenkang injection 30ml group (n = 30), Shenkang injection 60ml group (n = 31), Shenkang injection 100ml group (n = 35) and control group (n = 35). All the 4 groups were given the same routine supportive therapy and were treated with high flux hemodialysis. On this basis, the clinical effects of different doses of Shenkang injection were observed. The clinical efficacy, syndromes score, urinary conductivity, C-reactive protein, tumor necrosis factor- 伪, interleukin-6, adverse reactions, residual renal function and quality of life (QOL) were compared among the four groups. Results: the clinical efficacy, syndrome score, urine conductivity, C-reactive protein, tumor necrosis factor- 伪, interleukin-6, residual renal function and quality of life in Shenkang injection 100ml group were higher than those in Shenkang injection 30ml group. Shenkang injection 60 ml group and control group were significant; At the same time, urine conductivity was negatively correlated with urea nitrogen and creatinine and positively correlated with hemoglobin content in the four groups. In addition, there were no death cases or adverse drug reactions associated with Shenkang injection in the four groups. Conclusion: the electrical conductivity of patients with stage 5 chronic kidney disease is decreased, and there is microinflammation, which is positively correlated with the degree of renal failure. Shenkang injection 1.5ml/kg d diluted intravenous drip intervention in high throughput hemodialysis could significantly improve the clinical efficacy, syndrome score, electrical conductivity and microinflammatory state of patients with chronic kidney disease at 5 stages, and had less adverse reactions. It is of great significance to protect residual renal function and improve quality of life.
【作者单位】：海南省三亚市人民医院肾内科;海南医学院附属医院肾内科;
【分类号】：R277.5

【参考文献】